Abivax Shares Soar Another 5% and Record +53% Over the Week at SBF 120
The French biotech resumes trading in Paris with a strong increase, following the completion of its ADS offering in the United States. The stock takes a leading position in the SBF 120, following a significantly raised new analyst target. The Paris session is well-oriented.
Kepler Cheuvreux Raises Target to €180 Following US ADS Offering
Abivax shares gained 5.02% to €123.40, among the strongest rises in the SBF 120, following the resumption of trading after raising approximately $600 million in the United States. Trading had been temporarily suspended in Paris to finalize the public offering of American Depositary Shares on the Nasdaq. This operation extends the positive clinical results of obefazimod presented on June 30, for ulcerative colitis. Following this, Kepler Cheuvreux raised its price target from €130 to €180 on June 30, while maintaining its buy rating, representing a potential of nearly 46% compared to the current price. The company also indicated during the publication on June 29, 2026, that it is preparing to file this year its application for marketing authorization in the United States.
A Rally That Puts the Stock 40% Above Its MM20, with Heavy Shorts at 6.44%
The movement is part of a spectacular dynamic: +52.9% over the week and an increase of nearly eighteen-fold over a year. The price is significantly above its MM20 (€88.14), with a 40% gap, and is also well above the MM50 (€95.99) and MM200 (€96.29). The RSI at 69 is approaching the overbought threshold without yet crossing it, while the one-month volatility is high at 59, consistent with the magnitude of the post-clinical trial rebound. The next round level above is at €125, within reach of the current price. In parallel, according to statements reviewed, five funds accumulate 6.44% of the capital sold short, an exposure that has significantly increased over a month (+2.8 points). This level, substantially above the market average, indicates that institutional investors remain positioned against the stock or are looking to cover a long exposure, without being able to deduce a precise intention; the continuation of the rally could force some of these positions to unwind. The expected filing of the marketing authorization application in the United States will be the next fundamental step for the case.
